Vancomycin enhancement of experimental tobramycin nephrotoxicity. 1986

C A Wood, and S J Kohlhepp, and P W Kohnen, and D C Houghton, and D N Gilbert

The influence of vancomycin on tobramycin nephrotoxicity was assessed in male Fischer rats. Treatment groups included controls receiving diluent and groups receiving vancomycin alone at a dosage of 200 mg/kg (body weight) per day, tobramycin alone at a dosage of 80 mg/kg per day, and a combination of vancomycin and tobramycin at the above dosages. All regimens were injected on a twice-a-day schedule. The animals were sacrificed on days 1, 3, 10, 14, 17, and 21. When compared with controls, animals receiving vancomycin alone exhibited no detectable renal toxicity. Compared with the case with controls, tobramycin alone was toxic, as manifested by lower mean animal weights, increased blood urea nitrogen concentrations on days 14 and 17 (P less than 0.005), increased serum creatinine concentrations on days 17 and 21 (P less than 0.005), and the presence of renal cortical tubular necrosis and regeneration. When compared with tobramycin alone, the combination of vancomycin and tobramycin caused earlier and more severe toxicity. By day 10, the magnitude of weight loss, the rise in blood urea nitrogen, and the increase in serum creatinine concentration were all greater in the rats given the combination of vancomycin plus tobramycin than in the animals given tobramycin alone (P less than 0.005). In addition, there was more proximal tubular necrosis and regeneration in rats given vancomycin plus tobramycin compared with those given tobramycin alone. In this animal model, vancomycin alone caused no detectable renal injury, tobramycin alone produced minimal proximal tubular damage, and the combination of vancomycin and tobramycin resulted in a greater degree of kidney injury than observed with tobramycin alone.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D008297 Male Males
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D001806 Blood Urea Nitrogen The urea concentration of the blood stated in terms of nitrogen content. Serum (plasma) urea nitrogen is approximately 12% higher than blood urea nitrogen concentration because of the greater protein content of red blood cells. Increases in blood or serum urea nitrogen are referred to as azotemia and may have prerenal, renal, or postrenal causes. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984) BUN,Nitrogen, Blood Urea,Urea Nitrogen, Blood
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014031 Tobramycin An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. Nebramycin Factor 6,Brulamycin,Nebcin,Nebicin,Obracin,Tobracin,Tobramycin Sulfate,Sulfate, Tobramycin

Related Publications

C A Wood, and S J Kohlhepp, and P W Kohnen, and D C Houghton, and D N Gilbert
January 1985, Infection,
C A Wood, and S J Kohlhepp, and P W Kohnen, and D C Houghton, and D N Gilbert
January 1990, Antimicrobial agents and chemotherapy,
C A Wood, and S J Kohlhepp, and P W Kohnen, and D C Houghton, and D N Gilbert
June 1985, Antimicrobial agents and chemotherapy,
C A Wood, and S J Kohlhepp, and P W Kohnen, and D C Houghton, and D N Gilbert
April 1994, Antimicrobial agents and chemotherapy,
C A Wood, and S J Kohlhepp, and P W Kohnen, and D C Houghton, and D N Gilbert
August 1995, The Journal of pharmacology and experimental therapeutics,
C A Wood, and S J Kohlhepp, and P W Kohnen, and D C Houghton, and D N Gilbert
March 1976, Lancet (London, England),
C A Wood, and S J Kohlhepp, and P W Kohnen, and D C Houghton, and D N Gilbert
January 1983, Chemotherapy,
C A Wood, and S J Kohlhepp, and P W Kohnen, and D C Houghton, and D N Gilbert
April 1994, Antimicrobial agents and chemotherapy,
C A Wood, and S J Kohlhepp, and P W Kohnen, and D C Houghton, and D N Gilbert
September 1979, Lancet (London, England),
C A Wood, and S J Kohlhepp, and P W Kohnen, and D C Houghton, and D N Gilbert
January 1980, Lancet (London, England),
Copied contents to your clipboard!